Observational Study to Determine the Effectiveness and Safety of Vismodegib (ErivedgeÂ®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
The primary purpose for this multi-center, non-interventional study is to evaluate the duration of response defined as duration from first documented response of complete response (CR) or partial response (PR) until disease progression (as determined by the treating physician) for participants with laBCC.
Carcinoma, Basal Cell
DRUG: Vismodegib
Duration of Response, Defined as the Time from the First Assessment of CR or PR until Disease Progression or Death from any Cause, Whichever Occurs First, From first objective response until disease progression or death from any cause, up to 3 years
Percentage of Participants with Objective Response (CR or PR) as Determined by the Physician, From date of first therapy until disease progression or death, whichever occurs first (up to 3 years)|Percentage of Participants with Disease Control (CR, PR, or Stable Disease), From date of first therapy until disease progression or death, whichever occurs first (up to 3 years)|Percentage of Participants with Disease Reccurence, Defined as Participants who Achieve CR and later Progress, From date of first therapy until disease progression or death, whichever occurs first (up to 3 years)|Progression-Free Survival, Evaluated According to Physician's Assessments, From the date of first therapy to disease progression or death from any cause, up to 3 years|Overall Survival, From the date of the first therapy to death from any cause, up to 3 years|Time to Response, From the date of first therapy to first confirmed CR or PR whichever occurs first, up to 3 years|Percentage of Participants with Adverse Events, From Baseline up to 3 years
The primary purpose for this multi-center, non-interventional study is to evaluate the duration of response defined as duration from first documented response of complete response (CR) or partial response (PR) until disease progression (as determined by the treating physician) for participants with laBCC.